Five Star Equities Issues New Research Reports on CNAT, LXRX, OMED and OSIRadmin
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) shares soared 18.08 percent to close at $7.25 a share Tuesday. The stock traded between $7.21 and $8.20 on volume 1.24 million shares traded. The company announced that the FDA has granted Orphan Drug Designation to emricasan. Shares of Conatus Pharmaceuticals have fallen approximately 23.0 percent year-to-date.
Get more information on Conatus Pharmaceuticals and free access to the in-depth equity report at:
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) shares declined 4.74 percent to close at $2.241 a share Tuesday. The stock traded between $2.13 and $2.26 on volume 1.91 million shares traded. The company announced that a recent study has shown differences between placebo and LX1033, its treatment for IBS, in stool consistency were not statistically significant.
Get more information on Lexicon Pharmaceuticals and free access to the in-depth equity report at:
Oncomed Pharmaceuticals Inc. (NASDAQ: OMED) shares soared 97.86 percent to close at $27.70 a share Tuesday. The stock traded between $22.10 and $31.99 on volume 5.68 million shares traded. The company announced a strategic collaboration with Celgene Corp. to jointly develop and commercialize up to six anti-cancer stem cell product candidates.
Get more information on Oncomed Pharmaceuticals free access to the in-depth equity report at:
Osiris Therapeutics, Inc. (NASDAQ: OSIR) shares fell 7.60 percent to close at $15.45 a share Tuesday. The stock traded between $13.84 and $16.80 on volume of 1.20 million shares traded. The company announced that President and Chief Executive Officer C. Randal Mills, PhD. has stepped down from the company for personal reasons.
Get more information on Osiris Therapeutics and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor’s reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Posted: December 4th, 2013 under ACCESSWIRE.